Virogin Biotech, a Vancouver, Canada-based developer of next-generation oncolytic virus (OV) therapeutics, has raised over $120 million in a Series D2 round of financing as the company looks to build its global R&D centre in China’s Shanghai city.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
